SKINVISIBLE, INC.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation NV
Business Address 6320 S SANDHILL ROAD, LAS VEGAS, NV, 89120
Mailing Address 6320 S SANDHILL ROAD, LAS VEGAS, NV, 89120
Phone 702-433-7154
Fiscal Year End 1231
EIN 880344219
Financial Overview
FY2025
$158K
Total Assets
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 31, 2026 | View on SEC |
| 10-Q Quarterly financial report | November 13, 2025 | View on SEC |
| 10-Q Quarterly financial report | August 13, 2025 | View on SEC |
| 10-Q Quarterly financial report | May 14, 2025 | View on SEC |
| 10-K Annual financial report | April 14, 2025 | View on SEC |
Annual Reports
10-K March 31, 2026
- Proprietary Invisicare technology enables slow-release drug delivery for improved absorption and reduced irritation.
- QRX003 for Netherton Syndrome received FDA and European 'Orphan Drug' and 'Fast Track' status.
Related Companies
Companies in the same industry (SIC: 2834)
NERVGEN PHARMA CORP.
NGEN Pharmaceutical Preparations
Connect Biopharma Holdings Ltd
CNTB Pharmaceutical Preparations
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
LIXT Pharmaceutical Preparations
TuHURA Biosciences, Inc./NV
HURA Pharmaceutical Preparations
Canton Strategic Holdings, Inc.
CNTN Pharmaceutical Preparations
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.